Share

Low Socioeconomic Status Raises Pregnant Women’s Risk of Exposure to Thyroid-Disrupting Chemicals

Exposure to some endocrine-disrupting chemicals (EDCs) that harm the thyroid gland has increased over the past 20 years among U.S. women of childbearing age and pregnant women, especially among those with lower social and economic status, according to a study presented at ENDO 2024. The researchers focused this study on women who may be particularly...
Share

TED Patients Report Maintained Improvement 2 Years After Teprotumumab Infusions

Most patients with thyroid eye disease treated with teprotumumab didn’t require additional treatments nearly two years later, according to industry-supported research being presented Sunday at ENDO 2024 in Boston, Mass., and published in the journal Thyroid. “Thyroid eye disease is a lifelong autoimmune disease that can worsen or flare, regardless of how it has been treated....
Share

Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs to Be Presented at ENDO 2024

Five abstracts from Crinetics Pharmaceuticals’s clinical development programs, including four late-breaking abstracts, will be presented at the Endocrine Society’s annual meeting, ENDO 2024, taking place June 1-4, 2024 in Boston – including initial data from a Phase 2 Trial of atumelnant in congenital adrenal hyperplasia (CAH). “This year’s Endocrine Society meeting represents a major milestone for...
Share

Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Presented at ECE 2024

Neurocrine Biosciences, Inc. and Diurnal Ltd., a Neurocrine Biosciences company, in May presented baseline data from the CAHtalyst™ Phase 3 studies of crinecerfont in adult and pediatric patients with congenital adrenal hyperplasia (CAH), and modified-release hydrocortisone (Chronocort®) data for a Phase 2 clinical study (CHAMPAIN) in participants with primary adrenal insufficiency and in a Phase 3 extension study in...
Show More

As much as we know today about the endocrine system and the effects it has on the body, there remains so much that we do not know. Discoveries are made every day, and our understanding of the endocrine system is always growing and changing. Serving patients to the best of an endocrinologist’s abilities means being aware of all the latest developments in endocrine research. This includes the newest and most complete information concerning such endocrinology research topics as new treatments and new methods for disease prevention. Identifying symptoms and making the connections between those symptoms and endocrine disease can lead to greater understanding and ultimately better treatment for patients. More advanced prevention techniques can help patients stave off disease before it can impact their lives. Having the most current information can make a tremendous difference in the quality of life for your patients.

This section features some of the most current and forward-looking articles concerning the latest research in endocrinology. Written by and for endocrinologists, these articles are provided to keep you up to date with the most relevant developments in the field of endocrinology. You can access the information you need about new technology, new treatments and general information to help you serve your patients with better overall care. Our understanding of the endocrine system is always evolving. With Endocrine News, you can ensure that your knowledge of the field won’t be left behind. What’s more, your patients will always have access to the most advanced information out there.